 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 March 1995 | Volume 122 Issue 6 | Pages 401-408
Objective: To evaluate the association between resistance of human immunodeficiency virus type 1 (HIV-1) to zidovudine and clinical progression.
Design: Retrospective analysis of specimens from patients in the AIDS Clinical Trials Group (ACTG) protocol 116B/117, a randomized comparison of didanosine with continued zidovudine therapy in patients with advanced HIV-1 disease who had received 16 weeks or more of previous zidovudine therapy.
Setting: Participating ACTG virology laboratories.
Patients: 187 patients with baseline HIV-1 isolates.
Measurements: Zidovudine susceptibility testing and assays for syncytium-inducing phenotype were done on baseline HIV-1 isolates. Relative hazards for clinical progression or death associated with baseline clinical, virologic, and immunologic factors were determined from Cox proportional-hazards regression models.
Results: Compared with other patients, 15% (26 of 170) with isolates showing high-level zidovudine resistance (50% inhibitory zidovudine concentration
Conclusions: High-level resistance of HIV-1 to zidovudine predicted more rapid clinical progression and death when adjusted for other factors. However, patients with advanced HIV-1 disease may benefit from a change in monotherapy from zidovudine to didanosine whether high-level HIV-1 resistance to zidovudine is present or absent, and laboratory assessment of zidovudine resistance is not necessary for deciding when to switch monotherapy from zidovudine to didanosine.
Author and Article Information
From Massachusetts General Hospital, Beth Israel Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts. University of Alabama at Birmingham School of Medicine and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama. University of Colorado Health Sciences Center and Denver Veterans Affairs Medical Center, Denver, Colorado. National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland. University of California, San Francisco, and the San Francisco General Hospital AIDS Program, San Francisco, California. University of California, San Diego, and San Diego Veterans Affairs Medical Center, La Jolla, California.
ARTICLE
Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy
1.0 µmolars) had 1.74 times the risk for progressing to a new AIDS-defining event or death (95% CI, 1.00 to 3.03) and 2.78 times the risk for death (CI, 1.21 to 6.39) in analyses that controlled for baseline CD4+ T-lymphocyte count, syncytium-inducing HIV-1 phenotype, disease stage, and randomized treatment assignment. The clinical benefit of didanosine was not limited to patients with highly zidovudine-resistant baseline HIV-1 isolates.
For The AIDS Clinical Trials Group Protocol 116B/117 Team and The Virology Committee Resistance Working Group.
Requests for Reprints: Richard D'Aquila, MD, Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, MA 02129.
Acknowledgments: The authors thank Kimberly DeVore, Donna An, Lawrence Bechtel, Anu Savara (Massachusetts General Hospital, Boston, Massachusetts); D. Adam Plier, Mary Jane Burton (University of Alabama at Birmingham); Steven Kim, Linda Ecto (Beth Israel Hospital, New York, New York); Scott Bell, Russell Young, Piper Prach (University of Colorado Health Sciences Center, Denver, Colorado); Sara Albanil, Mary Ann del Fiorentino, Pat Ley (University of California, San Diego, La Jolla, California) for doing the laboratory studies; Elaine Gebhardt (ACTG Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts) for providing valuable logistical support; N.A. Roberts and Ian B. Duncan (Roche Products, Ltd., United Kingdom) for providing the saquinivir; and the work of investigators, clinicians, and virologists at each of the clinical sites participating in ACTG protocol 116B/117.
Grant Support: National Institutes of Health (AI 27659, AI 29193, AI 32775, AI 32770, AI 29173, AI 01101, AI 27670, AI 29164, AI 30457, and AI27664), the Research Center for AIDS and HIV Infection of the San Diego Veterans Affairs Medical Center, and Bristol-Myers Squibb Company. Dr. Johnson acknowledges core research facilities of the University of Alabama, Birmingham, Center for AIDS Research, and the Birmingham Veterans Administration Medical Center.
This article has been cited by other articles:
|
|
 |
|
  L. R. Miranda, M. Gotte, and D. R. Kuritzkes The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2648 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Garcia-Lerma, H. MacInnes, D. Bennett, H. Weinstock, and W. Heneine Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine J. Virol., July 15, 2004; 78(14): 7545 - 7552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Kuritzkes, R. M. Grant, P. Feorino, M. Griswold, M. Hoover, R. Young, S. Day, R. M. Lloyd Jr., C. Reid, G. F. Morgan, et al. Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System J. Clin. Microbiol., April 1, 2003; 41(4): 1594 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dybul, A. S. Fauci, J. G. Bartlett, J. E. Kaplan, and A. K. Pau Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV Ann Intern Med, September 3, 2002; 137(5_Part_2): 381 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Little, S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV N. Engl. J. Med., August 8, 2002; 347(6): 385 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Kuritzkes A fossil record of zidovudine resistance in transmitted isolates of HIV-1 PNAS, November 20, 2001; 98(24): 13485 - 13487. [Full Text] [PDF]
|
|
|
|
|
|
E.-Y. Kim, M. A. Winters, R. M. Kagan, and T. C. Merigan Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients J. Virol., November 15, 2001; 75(22): 11227 - 11233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Erali, S. Page, L. G. Reimer, and D. R. Hillyard Human Immunodeficiency Virus Type 1 Drug Resistance Testing: a Comparison of Three Sequence-Based Methods J. Clin. Microbiol., June 1, 2001; 39(6): 2157 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Little Is transmitted drug resistance in HIV on the rise? BMJ, May 5, 2001; 322(7294): 1074 - 1075. [Full Text]
|
|
|
|
 |
|
 R. Sharma Antiretroviral Resistance: Mechanisms, Detection and Clinical Implications Journal of Pharmacy Practice, December 1, 2000; 13(6): 442 - 456. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Basrur, Y. Song, S. J. Mazur, Y. Higashimoto, J. A. Turpin, W. G. Rice, J. K. Inman, and E. Appella Inactivation of HIV-1 Nucleocapsid Protein P7 by Pyridinioalkanoyl Thioesters. CHARACTERIZATION OF REACTION PRODUCTS AND PROPOSED MECHANISM OF ACTION J. Biol. Chem., May 12, 2000; 275(20): 14890 - 14897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Hirsch, F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, et al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel JAMA, May 10, 2000; 283(18): 2417 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Zolopa, R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed Ann Intern Med, December 7, 1999; 131(11): 813 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Little, E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, et al. Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection JAMA, September 22, 1999; 282(12): 1142 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Larder, S. Bloor, S. D. Kemp, K. Hertogs, R. L. Desmet, V. Miller, M. Sturmer, S. Staszewski, J. Ren, D. K. Stammers, et al. A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1961 - 1967. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Smith, G. J. Klarmann, K. M. Stray, U. K. von Schwedler, R. F. Schinazi, B. D. Preston, and T. W. North A New Point Mutation (P157S) in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level Resistance to (-)-beta -2',3'-Dideoxy-3'-Thiacytidine Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2077 - 2080. [Abstract] [Full Text]
|
|
|
|
|
|
P. Kosalaraksa, M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay J. Virol., July 1, 1999; 73(7): 5356 - 5363. [Abstract] [Full Text]
|
|
|
|
|
|
J. Martinez-Picado, A. V. Savara, L. Sutton, and R. T. D'Aquila Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 J. Virol., May 1, 1999; 73(5): 3744 - 3752. [Abstract] [Full Text]
|
|
|
|
|
|
G. Borkow, D. Arion, M. A. Wainberg, and M. A. Parniak The Thiocarboxanilide Nonnucleoside Inhibitor UC781 Restores Antiviral Activity of 3'-Azido-3'-Deoxythymidine (AZT) against AZT-Resistant Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., February 1, 1999; 43(2): 259 - 263. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kaul, B. Christofalo, R. H. Raymond, M. B. Stewart, and C. M. Macleod Effect of Food on the Bioavailability of Stavudine in Subjects with Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2295 - 2298. [Abstract] [Full Text]
|
|
|
|
|
|
J. J. McSharry, N. S. Lurain, G. L. Drusano, A. L. Landay, M. Notka, M. R. G. O'Gorman, A. Weinberg, H. M. Shapiro, P. S. Reichelderfer, and C. S. Crumpacker Rapid Ganciclovir Susceptibility Assay Using Flow Cytometry for Human Cytomegalovirus Clinical Isolates Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2326 - 2331. [Abstract] [Full Text]
|
|
|
|
|
|
A. S. Mulato, P. D. Lamy, M. D. Miller, W.-X. Li, K. E. Anton, N. S. Hellmann, and J. M. Cherrington Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1620 - 1628. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Wainberg and G. Friedland Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance JAMA, June 24, 1998; 279(24): 1977 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Hirsch, B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, et al. Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management JAMA, June 24, 1998; 279(24): 1984 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Kemp, C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, and B. A. Larder A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2',3'-Dideoxy-3'-Thiacytidine J. Virol., June 1, 1998; 72(6): 5093 - 5098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yerly, A. Rakik, S. Kinloch De Loes, B. Hirschel, D. Descamps, F. Brun-Vezinet, and L. Perrin Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants J. Virol., May 1, 1998; 72(5): 3520 - 3523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Smith, K. M. Remington, B. D. Preston, R. F. Schinazi, and T. W. North A Novel Point Mutation at Position 156 of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to the Combination of (-)-beta -2',3'-Dideoxy-3'-Thiacytidine and 3'-Azido-3'-Deoxythymidine J. Virol., March 1, 1998; 72(3): 2335 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Saravolatz, D. L. Winslow, G. Collins, J. S. Hodges, C. Pettinelli, D. S. Stein, N. Markowitz, R. Reves, M. O. Loveless, L. Crane, et al. Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter N. Engl. J. Med., October 10, 1996; 335(15): 1099 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Corey and K. K. Holmes Therapy for Human Immunodeficiency Virus Infection -- What Have We Learned? N. Engl. J. Med., October 10, 1996; 335(15): 1142 - 1144. [Full Text]
|
|
|
|
 |
|
 Roundtable: To Treat or Not to Treat -- Approaches to Antiretroviral Therapy AIDS Clinical Care, January 1, 1996; 1996(101): 1 - 1. [Full Text]
|
|
|
|
|
|
S. A. Danner, A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, et al. A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease N. Engl. J. Med., December 7, 1995; 333(23): 1528 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ueno, T. Shirasaka, and H. Mitsuya Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2`,3`-Dideoxynucleoside 5`-Triphosphates J. Biol. Chem., October 6, 1995; 270(40): 23605 - 23611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Antiretroviral Drug Resistance: Clinical Significance and Implications for HIV Pathogenesis AIDS Clinical Care, August 1, 1995; 1995(801): 1 - 1. [Full Text]
|
|
|
|
|
|
AZT Resistance and Disease Progression AIDS Clinical Care, May 1, 1995; 1995(501): 8 - 8. [Full Text]
|
|
Article
